Esperion’s NEXLETOL (bempedoic acid) Tablet Receives the US FDA’s Approval for Lowering Cholesterol Level
Esperion Reports Results of Bempedoic Acid in P-III Study 2 or 1002-047 for Patients with ASCVD or HeFH
Shots:
- The approval is based on P-III global pivotal Phase 3 LDL-C lowering program assessing NEXLETOL vs PBO in 3000+ patients corrected LDL-C lowering when used with moderate or high intensity statins., NEJM
- The study resulted in well-tolerated results, providing an average of 18% PBO corrected LDL-C lowering when used with moderate or high intensity statins
- NEXLETOL is novel orally administered once daily ATP Citrate Lyase (ACL) inhibitor involved in lowering LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors
Click here to read full press release/ article | Ref: Globe Newswire | Image: Behance